{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T10:52:12Z","timestamp":1786791132186,"version":"build-2736575974"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:00:00Z","timestamp":1662508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:00:00Z","timestamp":1662508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background of study<\/jats:title>\n                <jats:p>Globally, many reproductive aged women are affected by polycystic ovarian syndrome (PCOS), which is a common endocrine and metabolic disorder that is linked with adipose dysfunction and chronic low-grade inflammation. Spironolactone (SPL), a mineralocorticoid receptor blocker has been documented as a metabolic modulator. However, its immunomodulatory effect in PCOS is unknown. Therefore, the present study hypothesized that SPL would ameliorate adipose dysfunction and inflammation in experimental PCOS animals.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>Female Wistar rats that were 8\u00a0weeks old were allocated into three groups. Group 1 received vehicle (distilled water; <jats:italic>p.o.<\/jats:italic>), group 2 received letrozole (1\u00a0mg\/kg; <jats:italic>p.o.<\/jats:italic>) and group 3 received letrozole plus SPL (0.25\u00a0mg\/kg, <jats:italic>p.o<\/jats:italic>.). The administration was performed once daily for 21\u00a0days.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The experimental PCOS animals showed insulin resistance, hyperinsulinemia and hyperandrogenism as well as oxidative stress and elevated inflammatory biomarkers (NF-kB\/TNF-\/IL-6) as well as a significant decrease in triglycerides, total cholesterol, free fatty acids, GSH and G6PD in the adipose tissue of PCOS animals. In addition, immunohistochemical assessment of adipose tissue showed significant expression of BAX and inflammasome, indicating apoptosis and inflammation compared to control animals. Nevertheless, administration of SPL attenuated these perturbations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Altogether, the present study suggests that low-dose spironolactone confers protection against adipose dysfunction in experimental PCOS animals by attenuating inflammation, oxidative stress and cellular apoptosis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12902-022-01143-y","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T12:03:12Z","timestamp":1662552192000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Low-dose spironolactone ameliorates adipose tissue inflammation and apoptosis in letrozole-induced PCOS rat model"],"prefix":"10.1186","volume":"22","author":[{"given":"Stephanie E.","family":"Areloegbe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mmenyene U.","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mosunmola B.","family":"Oyeleke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8229-9688","authenticated-orcid":false,"given":"Kehinde S.","family":"Olaniyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,7]]},"reference":[{"issue":"6","key":"1143_CR1","first-page":"96","volume":"4","author":"AM Kabel","year":"2016","unstructured":"Kabel AM, Alghubayshi AY, Moharm FM. The impact of polycystic ovarian syndrome, a potential risk factor to endometrial cancer, on the quality of sleep. J Cancer Res Treat. 2016;4(6):96\u20138.","journal-title":"J Cancer Res Treat"},{"issue":"4","key":"1143_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.9734\/jammr\/2019\/v30i430190","volume":"30","author":"U Zafar","year":"2019","unstructured":"Zafar U, Memon Z, Moin K, Agha S, Hassan JA, Zehra D. Prevalence of PCOS with associated symptoms and complications at tertiary care hospital of Karachi. J Adv Med Med Res. 2019;30(4):1\u20139.","journal-title":"J Adv Med Med Res"},{"issue":"6","key":"1143_CR3","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1210\/jc.2003-032046","volume":"89","author":"R Azziz","year":"2004","unstructured":"Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89(6):2745\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1143_CR4","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1210\/er.2015-1104","volume":"37","author":"RL Rosenfield","year":"2016","unstructured":"Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev. 2016;37(5):467\u2013520.","journal-title":"Endocr Rev"},{"issue":"3","key":"1143_CR5","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/j.1471-0528.2010.02799.x","volume":"118","author":"VL Kumarapeli","year":"2011","unstructured":"Kumarapeli VL, Seneviratne RD, Wijeyaratne CN. Health-related quality of life and psychological distress in polycystic ovary syndrome: a hidden facet in South Asian women. BJOG. 2011;118(3):319\u201328.","journal-title":"BJOG."},{"issue":"1","key":"1143_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12920-021-01058-y","volume":"14","author":"Y Yu","year":"2021","unstructured":"Yu Y, Tan P, Zhuang Z, Wang Z, Zhu L, Qiu R, Xu H. Untargeted metabolomic approach to study the serum metabolites in women with polycystic ovary syndrome. BMC Med Genomics. 2021;14(1):1\u20135.","journal-title":"BMC Med Genomics"},{"issue":"10","key":"1143_CR7","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1210\/jc.2012-1382","volume":"97","author":"H Jones","year":"2012","unstructured":"Jones H, Sprung VS, Pugh CJ, Daousi C, Irwin A, Aziz N, Adams VL, Thomas EL, Bell JD, Kemp GJ, Cuthbertson DJ. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. J Clin Endocrinol Metab. 2012;97(10):3709\u201316.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1143_CR8","first-page":"179","volume":"11","author":"J Villa","year":"2011","unstructured":"Villa J, Pratley RE. Adipose tissue dysfunction in polycystic ovary syndrome. Curr DiabRep. 2011;11(3):179\u201384.","journal-title":"Curr DiabRep"},{"key":"1143_CR9","doi-asserted-by":"publisher","first-page":"745","DOI":"10.2147\/IJWH.S70314","volume":"7","author":"S Palomba","year":"2015","unstructured":"Palomba S, Santagni S, Falbo A, La Sala GB. Complications and challenges associated with polycystic ovary syndrome: current perspectives. Int J Women\u2019s Health. 2015;7:745.","journal-title":"Int J Women's Health"},{"issue":"7","key":"1143_CR10","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.tcm.2019.08.010","volume":"30","author":"O Osibogun","year":"2020","unstructured":"Osibogun O, Ogunmoroti O, Michos ED. Polycystic ovary syndrome and cardiometabolic risk: opportunities for cardiovascular disease prevention. Trends Cardiovasc Med. 2020;30(7):399\u2013404.","journal-title":"Trends Cardiovasc Med"},{"issue":"4","key":"1143_CR11","doi-asserted-by":"publisher","first-page":"4292","DOI":"10.4238\/2013.February.28.16","volume":"12","author":"SB Lecke","year":"2013","unstructured":"Lecke SB, Morsch DM, Spritzer PM. Association between adipose tissue expression and serum levels of leptin and adiponectin in women with polycystic ovary syndrome. Genet Mol Res. 2013;12(4):4292\u20136.","journal-title":"Genet Mol Res"},{"issue":"4","key":"1143_CR12","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1172\/JCI96139","volume":"128","author":"M Shimobayashi","year":"2018","unstructured":"Shimobayashi M, Albert V, Woelnerhanssen B, Frei IC, Weissenberger D, Meyer-Gerspach AC, Clement N, Moes S, Colombi M, Meier JA, Swierczynska MM. Insulin resistance causes inflammation in adipose tissue. J Clin Investig. 2018;128(4):1538\u201350.","journal-title":"J Clin Investig"},{"issue":"6","key":"1143_CR13","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.2337\/db06-1749","volume":"56","author":"S Nishimura","year":"2007","unstructured":"Nishimura S, Manabe I, Nagasaki M, Hosoya Y, Yamashita H, Fujita H, Ohsugi M, Tobe K, Kadowaki T, Nagai R, Sugiura S. Adipogenesis in obesity requires close interplay between differentiating adipocytes, stromal cells, and blood vessels. Diabetes. 2007;56(6):1517\u201326.","journal-title":"Diabetes"},{"issue":"7203","key":"1143_CR14","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nature07201","volume":"454","author":"R Medzhitov","year":"2008","unstructured":"Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008;454(7203):428\u201335.","journal-title":"Nature"},{"issue":"1","key":"1143_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1189\/jlb.0210072","volume":"88","author":"T Suganami","year":"2010","unstructured":"Suganami T, Ogawa Y. Adipose tissue macrophages: their role in adipose tissue remodeling. J Leukoc Biol. 2010;88(1):33\u20139.","journal-title":"J Leukoc Biol"},{"key":"1143_CR16","doi-asserted-by":"publisher","first-page":"747944","DOI":"10.3389\/fendo.2021.747944","volume":"12","author":"L Yao","year":"2021","unstructured":"Yao L, Wang Q, Zhang R, Wang X, Liu Y, Di F, Song L, Xu S. Brown adipose transplantation improves polycystic ovary syndrome-involved metabolome remodeling. Front Endocrinol. 2021;12:747944.","journal-title":"Front Endocrinol."},{"issue":"2","key":"1143_CR17","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.mce.2011.09.011","volume":"350","author":"V Marzolla","year":"2012","unstructured":"Marzolla V, Armani A, Zennaro MC, Cinti F, Mammi C, Fabbri A, Rosano GM, Caprio M. The role of the mineralocorticoid receptor in adipocyte biology and fat metabolism. Mol Cell Endocrinol. 2012;350(2):281\u20138.","journal-title":"Mol Cell Endocrinol"},{"issue":"3","key":"1143_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.tem.2019.11.006","volume":"31","author":"A Feraco","year":"2020","unstructured":"Feraco A, Marzolla V, Scuteri A, Armani A, Caprio M. Mineralocorticoid receptors in metabolic syndrome: from physiology to disease. Trends Endocrinol Metab. 2020;31(3):205\u201317.","journal-title":"Trends Endocrinol Metab"},{"issue":"9","key":"1143_CR19","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1093\/cvr\/cvx097","volume":"113","author":"G Jia","year":"2017","unstructured":"Jia G, Aroor AR, Sowers JR. The role of mineralocorticoid receptor signaling in the cross-talk between adipose tissue and the vascular wall. Cardiovasc Res. 2017;113(9):1055\u201363.","journal-title":"Cardiovasc Res"},{"issue":"2","key":"1143_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11906-013-0414-8","volume":"16","author":"MI Danjuma","year":"2014","unstructured":"Danjuma MI, Mukherjee I, Makaronidis J, Osula S. Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles. Curr Hypertens Rep. 2014;16(2):1.","journal-title":"Curr Hypertens Rep"},{"issue":"2","key":"1143_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41371-020-00467-3","volume":"35","author":"M Thuzar","year":"2021","unstructured":"Thuzar M, Stowasser M. The mineralocorticoid receptor\u2014an emerging player in metabolic syndrome? J Hum Hypertens. 2021;35(2):117\u201323.","journal-title":"J Hum Hypertens"},{"issue":"9","key":"1143_CR22","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1345\/aph.1G025","volume":"39","author":"NA Christy","year":"2005","unstructured":"Christy NA, Franks AS, Cross LB. Spironolactone for hirsutism in polycystic ovary syndrome. Ann Pharmacother. 2005;39(9):1517\u201321.","journal-title":"Ann Pharmacother"},{"issue":"13","key":"1143_CR23","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1080\/14656566.2016.1215430","volume":"17","author":"D Armanini","year":"2016","unstructured":"Armanini D, Andrisani A, Bordin L, Sabbadin C. Spironolactone in the treatment of polycystic ovary syndrome. Expert Opin Pharmacother. 2016;17(13):1713\u20135.","journal-title":"Expert Opin Pharmacother"},{"issue":"9","key":"1143_CR24","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s40618-016-0466-0","volume":"39","author":"C Sabbadin","year":"2016","unstructured":"Sabbadin C, Andrisani A, Zermiani M, Don\u00e0 G, Bordin L, Ragazzi E, Boscaro M, Ambrosini G, Armanini D. Spironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI. J Endocrinol Invest. 2016;39(9):1015\u201321.","journal-title":"J Endocrinol Invest"},{"issue":"9","key":"1143_CR25","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1210\/jc.2013-1040","volume":"98","author":"MA Ganie","year":"2013","unstructured":"Ganie MA, Khurana ML, Nisar S, Shah PA, Shah ZA, Kulshrestha B, Gupta N, Zargar MA, Wani TA, Mudasir S, Mir FA. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study. J Clin Endocrinol Metab. 2013;98(9):3599\u2013607.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1143_CR26","doi-asserted-by":"publisher","first-page":"206","DOI":"10.2174\/1874467212666191113150553","volume":"13","author":"FA Mayyas","year":"2020","unstructured":"Mayyas FA, Aljohmani AI, Alzoubi KH. The impact of spironolactone on markers of myocardial oxidative status, inflammation and remodeling in hyperthyroid rats. Curr Mol Pharmacol. 2020;13(3):206\u201315.","journal-title":"Curr Mol Pharmacol"},{"key":"1143_CR27","doi-asserted-by":"publisher","first-page":"108742","DOI":"10.1016\/j.cbi.2019.108742","volume":"310","author":"OA Adeyanju","year":"2019","unstructured":"Adeyanju OA, Falodun TO, Fabunmi OA, Olatunji LA, Soladoye AO. Very low dose spironolactone protects experimentally-induced polycystic ovarian syndrome from insulin-resistant metabolic disturbances by suppressing elevated circulating testosterone. Chem Biol Interact. 2019;310:108742.","journal-title":"Chem Biol Interact"},{"issue":"411","key":"1143_CR28","doi-asserted-by":"publisher","first-page":"115381","DOI":"10.1016\/j.taap.2020.115381","volume":"15","author":"KS Olaniyi","year":"2021","unstructured":"Olaniyi KS, Oniyide AA, Adeyanju OA, Ojulari LS, Omoaghe AO, Olaiya OE. Low dose spironolactone-mediated androgen-adiponectin modulation alleviates endocrine-metabolic disturbances in letrozole-induced PCOS. Toxicol Appl Pharmacol. 2021;15(411):115381.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"2","key":"1143_CR29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.arcmed.2003.10.005","volume":"35","author":"H Kafali","year":"2004","unstructured":"Kafali H, Iriadam M, Ozardal\u0131 I, Demir N. Letrozole-induced polycystic ovaries in the rat: a new model for cystic ovarian disease. Arch Med Res. 2004;35(2):103\u20138.","journal-title":"Arch Med Res"},{"key":"1143_CR30","doi-asserted-by":"publisher","first-page":"120560","DOI":"10.1016\/j.lfs.2022.120560","volume":"300","author":"KS Olaniyi","year":"2022","unstructured":"Olaniyi KS, Areloegbe SE. Suppression of PCSK9\/NF-kB-dependent pathways by acetate ameliorates cardiac inflammation in a rat model of polycystic ovarian syndrome. Life Sci. 2022;300:120560.","journal-title":"Life Sci"},{"issue":"316","key":"1143_CR31","doi-asserted-by":"publisher","first-page":"108929","DOI":"10.1016\/j.cbi.2019.108929","volume":"25","author":"EO Dangana","year":"2020","unstructured":"Dangana EO, Omolekulo TE, Areola ED, Olaniyi KS, Soladoye AO, Olatunji LA. Sodium acetate protects against nicotine-induced excess hepatic lipid in male rats by suppressing xanthine oxidase activity. Chem Biol Interact. 2020;25(316):108929.","journal-title":"Chem Biol Interact"},{"issue":"23","key":"1143_CR32","doi-asserted-by":"publisher","first-page":"3498","DOI":"10.3748\/wjg.v11.i23.3498","volume":"11","author":"JY Zheng","year":"2005","unstructured":"Zheng JY, Yang GS, Wang WZ, Li J, Li KZ, Guan WX, Wang WL. Overexpression of Bax induces apoptosis and enhances drug sensitivity of hepatocellular cancer-9204 cells. World J Gastroenterol: WJG. 2005;11(23):3498.","journal-title":"World J Gastroenterol: WJG"},{"issue":"1","key":"1143_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-64062-9","volume":"10","author":"C Pisani","year":"2020","unstructured":"Pisani C, Ramella M, Boldorini R, Loi G, Billia M, Boccafoschi F, Volpe A, Krengli M. Apoptotic and predictive factors by Bax, Caspases 3\/9, Bcl-2, p53 and Ki-67 in prostate cancer after 12 Gy single-dose. Sci Rep. 2020;10(1):1.","journal-title":"Sci Rep"},{"issue":"4","key":"1143_CR34","first-page":"1113","volume":"43","author":"S Yu","year":"2020","unstructured":"Yu S, Yin JJ, Miao JX, Li SG, Huang CZ, Huang N, Fan TL, Li XN, Wang YH, Han SN, Zhang LR. Activation of NLRP3 inflammasome promotes the proliferation and migration of esophageal squamous cell carcinoma. Oncol Rep. 2020;43(4):1113\u201324.","journal-title":"Oncol Rep"},{"issue":"1","key":"1143_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1742-4755-12-7","volume":"12","author":"AS Jamil","year":"2015","unstructured":"Jamil AS, Alalaf SK, Al-Tawil NG, Al-Shawaf T. A case\u2013control observational study of insulin resistance and metabolic syndrome among the four phenotypes of polycystic ovary syndrome based on Rotterdam criteria. Reprod Health. 2015;12(1):1\u20139.","journal-title":"Reprod Health"},{"issue":"1","key":"1143_CR36","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1210\/jc.2005-1696","volume":"91","author":"F Gonz\u00e1lez","year":"2006","unstructured":"Gonz\u00e1lez F, Rote NS, Minium J, Kirwan JP. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91(1):336\u201340.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1143_CR37","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.fertnstert.2011.11.036","volume":"97","author":"JC Marshall","year":"2012","unstructured":"Marshall JC, Dunaif A. Should all women with PCOS be treated for insulin resistance? Fertil Steril. 2012;97(1):18\u201322.","journal-title":"Fertil Steril"},{"issue":"5","key":"1143_CR38","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1210\/er.2015-1018","volume":"36","author":"DA Dumesic","year":"2015","unstructured":"Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr Rev. 2015;36(5):487\u2013525.","journal-title":"Endocr Rev"},{"key":"1143_CR39","doi-asserted-by":"crossref","unstructured":"Engin AB. Adipocyte-macrophage cross-talk in obesity. Obesity and lipotoxicity. 2017:327\u201343.","DOI":"10.1007\/978-3-319-48382-5_14"},{"issue":"3","key":"1143_CR40","doi-asserted-by":"publisher","first-page":"137","DOI":"10.5468\/ogs.2013.56.3.137","volume":"56","author":"JJ Kim","year":"2013","unstructured":"Kim JJ, Choi YM. Dyslipidemia in women with polycystic ovary syndrome. Obstetrics & gynecology science. 2013;56(3):137\u201342.","journal-title":"Obstetrics & gynecology science"},{"issue":"10","key":"1143_CR41","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/ni.1920","volume":"11","author":"T Satoh","year":"2010","unstructured":"Satoh T, Takeuchi O, Vandenbon A, Yasuda K, Tanaka Y, Kumagai Y, Miyake T, Matsushita K, Okazaki T, Saitoh T, Honma K. The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat Immunol. 2010;11(10):936\u201344.","journal-title":"Nat Immunol"},{"issue":"12","key":"1143_CR42","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3109\/09513590.2012.683082","volume":"28","author":"E Deligeoroglou","year":"2012","unstructured":"Deligeoroglou E, Vrachnis N, Athanasopoulos N, Iliodromiti Z, Sifakis S, Iliodromiti S, Siristatidis C, Creatsas G. Mediators of chronic inflammation in polycystic ovarian syndrome. Gynecol Endocrinol. 2012;28(12):974\u20138.","journal-title":"Gynecol Endocrinol"},{"issue":"9","key":"1143_CR43","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1172\/JCI34260","volume":"118","author":"S Schenk","year":"2008","unstructured":"Schenk S, Saberi M, Olefsky JM. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Investig. 2008;118(9):2992\u20133002.","journal-title":"J Clin Investig"},{"issue":"8","key":"1143_CR44","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1089\/met.2015.0044","volume":"13","author":"MH Hwang","year":"2015","unstructured":"Hwang MH, Yoo JK, Luttrell M, Meade TH, English M, Christou DD. Effect of selective mineralocorticoid receptor blockade on flow-mediated dilation and insulin resistance in older adults with metabolic syndrome. Metab Syndr Relat Disord. 2015;13(8):356\u201361.","journal-title":"Metab Syndr Relat Disord"},{"key":"1143_CR45","doi-asserted-by":"publisher","first-page":"8589318","DOI":"10.1155\/2016\/8589318","volume":"2016","author":"T Zuo","year":"2016","unstructured":"Zuo T, Zhu M, Xu W. Roles of oxidative stress in polycystic ovary syndrome and cancers. Oxid Med Cell Longev. 2016;2016:8589318.","journal-title":"Oxid Med Cell Longev"},{"issue":"8","key":"1143_CR46","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.jash.2016.05.013","volume":"10","author":"JV Zhao","year":"2016","unstructured":"Zhao JV, Xu L, Lin SL, Schooling CM. Spironolactone and glucose metabolism, a systematic review and meta-analysis of randomized controlled trials. J Am Soc Hypertens. 2016;10(8):671\u201382.","journal-title":"J Am Soc Hypertens"},{"issue":"3","key":"1143_CR47","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1161\/HYPERTENSIONAHA.116.07911","volume":"68","author":"JA Victorio","year":"2016","unstructured":"Victorio JA, Clerici SP, Palacios R, Alonso MJ, Vassallo DV, Jaffe IZ, Rossoni LV, Davel AP. Spironolactone prevents endothelial nitric oxide synthase uncoupling and vascular dysfunction induced by \u03b2-adrenergic overstimulation: role of perivascular adipose tissue. Hypertension. 2016;68(3):726\u201335.","journal-title":"Hypertension"},{"issue":"9","key":"1143_CR48","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1002\/ejhf.792","volume":"19","author":"A Olivier","year":"2017","unstructured":"Olivier A, Pitt B, Girerd N, Lamiral Z, Machu JL, McMurray JJ, Swedberg K, van Veldhuisen DJ, Collier TJ, Pocock SJ, Rossignol P. Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial. Eur J Heart Fail. 2017;19(9):1186\u201397.","journal-title":"Eur J Heart Fail."}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-022-01143-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-022-01143-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-022-01143-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T19:04:59Z","timestamp":1668798299000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-022-01143-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,7]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1143"],"URL":"https:\/\/doi.org\/10.1186\/s12902-022-01143-y","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,7]]},"assertion":[{"value":"14 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. The protocol was approved by the Institutional Ethical Review Board of Afe Babalola University (Ado-Ekiti, Nigeria). Consent to participate is not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors participated and agreed to the submission.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"224"}}